Abrdn Life Sciences Investors (HQL) Technical Analysis
$16.17▲1.06%
Market is closed - opens 7 PM, 14 Oct 2025
Insights
- Abrdn Life Sciences Investors is currently in a favorable trading position ( BUY ) according to technical analysis indicators.
- Based on analysis of the Oscillators technical indicator, the current market trend for Abrdn Life Sciences Investors stock suggests that it is a good time to sell or bad time to initiate a fresh position
- Based on analysis of the Moving Averages technical indicator, Abrdn Life Sciences Investors stock is in a uptrend ↗️
- Based on analysis of the Pivot Points, the current market trend for Abrdn Life Sciences Investors stock suggests that it is a good time to buy
Analysis Summary
Oscillators
Sell
Neutral
Buy
Moving Averages
Sell
Neutral
Buy
Pivots
Sell
Neutral
Buy
Oscillators
Name | Value | Action |
|---|---|---|
Relative Strength Index | 75.43 | Sell |
Stochastic | 89.4, 93.3 | Sell |
Ultimate Oscillator | 57.57 | Neutral |
Stochastic Relative Strength Index | 79.62, 78.71 | Neutral |
Moving Average Convergence Divergence | 0.54, 0.45 | Buy |
Moving Averages
Simple Moving Average
Period (Days) | Value | Action |
|---|---|---|
10 | 15.74 | Buy |
20 | 14.96 | Buy |
50 | 14.26 | Buy |
Exponential Moving Average
Period (Days) | Value | Action |
|---|---|---|
10 | 15.65 | Buy |
20 | 15.2 | Buy |
50 | 14.45 | Buy |
Volume Weighted Moving Average
Period (Days) | Value | Action |
|---|---|---|
10 | 15.7 | Neutral |
20 | 15.07 | Buy |
50 | 14.54 | Buy |
Double Exponential Moving Average
Period (Days) | Value | Action |
|---|---|---|
10 | 16.13 | Buy |
20 | 15.9 | Buy |
50 | 15.33 | Buy |
Triple Exponential Moving Average
Period (Days) | Value | Action |
|---|---|---|
10 | 16.17 | Buy |
20 | 16.14 | Buy |
50 | 15.68 | Buy |
Pivot
Pivot | Value |
|---|---|
Resistance L3 | 16.41 |
Resistance L2 | 16.32 |
Resistance L1 | 16.21 |
Pivot Point | 16.12 |
Support L1 | 16.01 |
Support L2 | 15.92 |
Support L3 | 15.81 |
*Disclaimer: The content present here is for informational purposes only, you should not construe any such information or other material as investment advisory.